GTC Biotherapeutics (fka GTCB)

[ThomasS]

"...it looks like GTC expects the amount to be received in 4Q07 from the US ATryn partner to be in the $6-8M range. The key to the economics of the partnership deal will of course be the clinical and regulatory milestone payments, particularly in the DIC indication."

Upon further reflection, I feel these milestones may be quite large. I've assumed already here that the "middle-ground" for negotiations is huge milestones with sub-optimal royalties and little upfront cash. But, this requires nice milestone payments, which may be larger than even I had assumed.

I'm excited that we may know within the next 30 days... and it's an interesting negotiating dilemma for GTC, although all positive options.